CagriSema: women lost 25% of body weight on average in a new Novo analysis
A post-trial analysis of about 2,300 women in Novo's phase 3 study found 25% average weight loss at 68 weeks on CagriSema versus 3% on placebo, assuming everyone stayed on treatment, with similar results before, during and after menopause. Novo says more work is needed to confirm the findings; the jab is expected to launch early next year.
Image credit: CNBC
Source: CNBC (20 Oct 2026).